Study links low hematocrit to loss of Crohns remission A low hematocrit was linked to a shorter time to loss of remission for Crohns disease patients taking certolizumab pegol compared with patients who had normal hematocrit, according to a study by the IBD Center at the University of California, San Diego. Study author Dr. William Sandborn said the data are comparable to observations that low serum albumin also may be a remission risk factor. Colombel JF. P-039. Presented at: 2014 Advances in Inflammatory Bowel Diseases, Dec. 4-6, 2014; Orlando, Fla.
Posted on: Fri, 12 Dec 2014 03:41:41 +0000
Trending Topics
Recently Viewed Topics
© 2015